Homepage > Company > Media > Pharma News > 2024 > Lantern Pharma Highlights Promising Preclinical Results of LP-184’s

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s

Lantern Pharma, a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement demonstrating the preclinical synergy of LP-184 with checkpoint inhibitors and the ability of LP-184 to resensitize tumors that have become non-responsive to Anti-PD1 therapies.

The company will be presenting preliminary data from the recent work done in conjunction with Drs. Yong Du and Shiaw-Yih (Phoebus) Lin at MD Anderson at The Immuno-Oncology Summit 2024 in Philadelphia.

The data will be presented in the form of poster entitled, LP-184, a Novel Acylfulvene, Sensitizes Immuno-Refractory Triple Negative Breast Cancers (TNBCs) To Anti-PD1 Therapy by Affecting the Tumor Microenvironment, (assigned Poster # P17). The poster highlights the following key points:

Ø LP-184 seems to potentiate anti-PD1 response in a mouse model of TNBC that is non-hypermutated and resistant to immunotherapy in the absence of LP-184.

Ø LP-184 can potentially transform immunologically “cold” tumors (non-responsive to IO therapies) into “hot” tumors (responsive to IO therapies) by modulating T cell activity in the tumor microenvironment and inducing a replication stress response defect.

Ø LP-184 seems to reshape the tumor microenvironment (TME) by significantly reducing the amount of M2 macrophages – which are associated with tumor drug resistance, tumor cell proliferation and are involved in helping the tumor cells escape immune cell death.

Ø LP-184 combined with an anti-PD1 agent elicited a greater anti-tumor response than monotherapies in mouse TNBC tumors that are non-hypermutated and resistant to immune checkpoint inhibitors.

LP-184 is being investigated in an ongoing first-in-human Phase 1 trial (NCT05933265) in advanced recurrent solid tumors to establish a maximum tolerated dose and assess its overall safety and suitability in more targeted cancer indications, including TNBC.

August 9, 2024

Read also

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across...

Enhertu by AstraZeneca, Daiichi wins new approval in China

AstraZeneca PLC on Monday said that its antibody drug conjugate Enhertu won another approval in China. The Cambridge, England-based pharmaceutical company said that the National Medical Products Admin...

CEPI-backed trial of Rift Valley fever jab starts in Kenya

A promising vaccine candidate for Rift Valley fever (RVF) has been advanced into a phase 2 trial in Kenya, the first time that a shot has reached this stage of development in a country where t...

Catalent (CTLT) to Sell Somerset, NJ Oral Solids Facility

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to s...